BIO-RAD NORWAY AS
Leading Life Science Research & Clinical Diagnostics | Bio-Rad
Bio-Rad is a global leader in developing and manufacturing a wide range of products for the life science research and clinical diagnostic markets.
Keywords
pharmaceuticalshospital equipmentorthopedic articles
Organization
- CEO
- OH
- Chairman of the board
- OH
- Years since formation
- 8 years
- since Dec 9, 2017
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 6
Ownership
- Number of shares and share classes
- 300
- 1 share class
- Total number of shareholders
- 1
- person
Financials
- Total operating income 2024
- 60,318,144
- NOK
- Annual total result 2024
- 1,488,639
- NOK
- Total equity 2024
- 5,473,553
- NOK
Last update: Aug 14, 2025
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
OH | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
OH | Chairman | - |
JM | Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - | |
| Accountant | - |
Last update: Nov 21, 2024
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 300 | 100 % |
Last update: Jun 2, 2025
Financials
in NOK
Summary
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 60,318,144 | 55,139,623 | 59,283,191 | 56,845,383 |
Annual Total Result | 1,488,639 | 1,432,407 | 807,151 | -731,125 |
Total assets | 13,734,713 | 12,701,502 | 17,779,223 | 18,174,343 |
Total liabilities | 8,261,161 | 8,716,589 | 15,226,716 | 16,428,987 |
Total equity | 5,473,553 | 3,984,914 | 2,552,507 | 1,745,356 |
P&L
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 60,318,144 | 55,139,623 | 59,283,191 | 56,845,383 |
Total operating costs | 58,997,258 | 53,745,993 | 58,505,575 | 57,848,543 |
Operating result | 1,320,886 | 1,393,630 | 777,616 | -1,003,160 |
Financial income/costs | 587,710 | 454,413 | 256,969 | 65,820 |
Profit before tax | 1,908,596 | 1,848,043 | 1,034,586 | -937,340 |
Total tax & extraordinary income/cost | 419,957 | 415,636 | 227,435 | -206,215 |
Annual Total Result | 1,488,639 | 1,432,407 | 807,151 | -731,125 |
Balance overview
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total fixed assets | 680,849 | 621,876 | 686,729 | 1,684,157 |
Total current assets | 13,053,865 | 12,079,627 | 17,092,493 | 16,490,185 |
Total assets | 13,734,713 | 12,701,502 | 17,779,223 | 18,174,343 |
Short term debt | 8,261,161 | 8,716,589 | 14,795,685 | 16,137,305 |
Long term debt | 0 | 0 | 431,032 | 291,682 |
Total liabilities | 8,261,161 | 8,716,589 | 15,226,716 | 16,428,987 |
Contributed capital | 30,000 | 30,000 | 30,000 | 30,000 |
Retained earnings | 5,443,553 | 3,954,914 | 2,522,507 | 1,715,356 |
Total equity | 5,473,553 | 3,984,914 | 2,552,507 | 1,745,356 |
Total equity and liabilities | 13,734,713 | 12,701,502 | 17,779,223 | 18,174,343 |
Classification
Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
G
Main industrial area
Wholesale and retail trade; repair of motor vehicles and motorcycles
46
Activity
Wholesale trade, except of motor vehicles and motorcycles
46.4
Main industrial group
Wholesale of household goods
46.46
Industrial group
Wholesale of pharmaceutical goods
46.460
Industrial group
Wholesale of pharmaceutical goods